Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae
Antimicrobial Agents and Chemotherapy · 07.10.2026 · 70 (10)
DOI: 10.1128/aac.00766-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.10.2026. Verfasst von Aditi Mukherjee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: DNA Gyrase, Neisseria gonorrhoeae, Fluoroquinolones, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Neisseria gonorrhoeae is a major public health concern due to its high global prevalence and rapid evolution of antibiotic resistance. A first-in-class topoisomerase inhibitor, zoliflodacin (a spiropyrimidinetrione), recently received FDA approval for treatment of gonorrhea, but its potential for cross-resistance with another topoisomerase inhibitor, the fluoroquinolone antibiotic ciprofloxacin, remains poorly understood. Here, we investigated how genetic diversity in the fluoroquinolone target gyrA influences the resistance and fitness effects of the zoliflodacin resistance mutation gyrB D429N . We constructed an isogenic panel of N. gonorrhoeae to determine how the resistance and fitness effects of the gyrB D429N mutation are modulated by the most common ciprofloxacin resistance-associated variants in gyrA . In the presence of gyrB D429N , the zoliflodacin minimum inhibitory concentration (MIC) was two- to fourfold higher in strains that also contained ciprofloxacin resistance-associated gyrA alleles, and the gyrB D429N mutation reciprocally increased ciprofloxacin MICs of these strains three- to sixfold. The fitness cost of the gyrB D429N mutation varied from modest to severe across gyrA backgrounds, with the largest cost in ciprofloxacin-resistant gyrA 91F/95G and gyrA 91F/95N backgrounds and comparatively minimal cost in the ciprofloxacin-resistant gyrA 91F/95A background. These results demonstrate the capacity for epistatic interactions among resistance-associated gyrA and gyrB mutations, underscoring the need for genomic surveillance to monitor high-risk combinations of resistance determinants as new therapies are deployed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
ORCID-Profile: Aditi Mukherjee, Bailey Bowcutt, Samantha G Palace, Yonatan H Grad
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Mukherjee, A., Blomqvist, S. O. P., Helekal, D., Rubin, D. H. F., Bowcutt, B., Palace, S. G., & Grad, Y. H. (2026). Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 70(10). https://doi.org/10.1128/aac.00766-26
Vancouver
Mukherjee A, Blomqvist SOP, Helekal D, Rubin DHF, Bowcutt B, Palace SG, et al. Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy. 2026;70(10). doi:10.1128/aac.00766-26
BibTeX
@article{Mukherjee2026,
author = {Mukherjee, Aditi and Blomqvist, Sofia O P and Helekal, David and Rubin, Daniel H F and Bowcutt, Bailey and Palace, Samantha G and Grad, Yonatan H},
title = {Fluoroquinolone resistance-conferring gyrA variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation gyrB D429N in Neisseria gonorrhoeae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {10},
doi = {10.1128/aac.00766-26}
}
EUVIMED